RE:Ate’s problem. gourt12 wrote: Antibe's biggest problem is their lack of investor engagement. Now i get they are in a lul period where we need to wait a few months for news, but they could even just explain their releases more.
As in this amalgamation a company statement on why this is good and how it futures plans. Last offering explaining excitedly how it will allow them to spring forward on different new trials etc. Just taking a release and pushing it in a more positive direction. Helps prevent the drops during quiet times.
I'm going to make a bold predicition ... don't beat me if it doesn't happen. Just a thought.
Successful Phase 3 will change investor perception of Antibe.
If management truly believes in their first product, they will connect all future (or most future) agreements to the success of Phase 3.
By then ... not only do you have a full blockbuster going to market, you also have 352 results from the first human studies (along with a potential fast-track). You also have good data on 340/parallel program as it ramps towards human studies.
If you can't hypnotize investors into buying shares (like GME has magically done), you ram it down their throats. You show them successful Phase 3 results. That is also a perfectly legitimate way to force the share price up. I'm guessing investors come around before the end of Phase 3 but we're just not good at making such predictions successfully.
Recently Dan said these things and they should noted ...
1. w.r.t. 352 ... moving forward rapidly (meaning there is a focus here).
2. When discussing 340, said they are working on a new patent for follow-on drug (that is key and it relates to the parallel program mentioned above).
3. w.r.t. COVID, they are working with a lot of effort as they go after lung inflammation. This goes well beyon COVID as it may have many applications/indications for lung inflammation in general.
With the cash we now have - seems we're going to force "value" by demonstrating our value.
Investors figure they have time ... that's why no one is rushing to buy right now. That could change quickly but it's going to take some exciting stuff to get shareholders off the sidelines.
IMO